A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib


Peking University

Status and phase

Phase 2




Drug: orelabrutinib

Study type


Funder types



Slowly responding switch IIT

Details and patient eligibility


This is a single arm, multi-center study to evaluate the efficacy and safety of orelabrutinib for Chronic lymphocytic lymphoma(CLL)/small lymphocytic lymphoma (SLL) patients who are slowly responding to Ibrutinib switched to Orelabrutinib.

Full description

The eligible CLL/SLL patients who are slowly responding to Ibrutinib will be switched to Orelabrutinib treatment. The patients will receive Orelabrutinib 150mg oral daily (28 days/cycle) for up to 2 year or until disease progression, intolerable toxicity, death, informed consent withdrawal or lost of follow up (whichever occurs first).


30 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Age ≥18 years old, male or female
  • Diagnosed as CLL/SLL based on iwCLL2018 criteria
  • Enhanced computed tomography/magnetic resonance imaging (CT/MRI) detection had measurable lesions: at least one lymph node had a maximum axis of more than 1.5 cm and had a measurable vertical dimension
  • ECOG score 0-2
  • Slowly responding to ibrutinib is defined as: patients only achieve SD after 3 cycles of ibrutinib treatment
  • Life expectancy ≥6 months
  • Adequate bone marrow reserve and adequate organ function
  • Participant or his/her legal agent must be willing to sign a written informed consent document.

Exclusion criteria

  • Evidence of active Richter's transformation or any evidence of disease progression on ibrutinib therapy.
  • CNS involvement by CLL
  • Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or metastasis in the last 5 years
  • Uncontrolled or significant cardiovascular disease
  • Active hemorrhage within 2 months prior screening
  • Cerebral ischemic stroke or bleeding within 6 months prior screening
  • Other surgery history within 6 weeks prior screening
  • Uncontrolled active systemic fungal, bacterial, virus or other microbe infection, or intravenous injection of antibiotics needed
  • Anti-tumor corticosteroids treatment 1 week prior orelabrutinib and anti-tumor herbal medicine treatment within 4 weeks prior screening
  • Activated or uncontrolled hepatitis virus B infection (HBsAg positive with/or HBc Ab positive and HBV-DNA titration positive), HCV-RNA positive, HIV positive.
  • Accepted live vaccine or immunization within 4 weeks prior screening
  • Medium / strong inhibition or induction of cytochrome P450 CYP3A is needed.
  • Allergy to orelabrutinib or the subsidiary (or supplementary) material (Hydroxypropyl methylcellulose acetate succinate, mannitol, cross-linked sodium carboxymethylcellulose, hydroxypropyl cellulose, silica and magnesium stearate)
  • Obvious gastro-bowel disease which may influence the intaking, transportation or absorption of the drug, or total gastrectomy.
  • Pregnant or breeding women, or women of childbearing age who are unwilling to take contraceptive measures during the whole study period and within 180 days after the last administration of the study drug; non surgically sterilized men who are unwilling to take contraceptive measures during the whole study period and within 180 days of the last administration of the study drug.
  • Potentially life-threatening situation, or severe organ dysfunction, or situations the researchers think not suitable for the trial
  • Any mental or cognitive impairment which may limit the understanding and implementation of informed consent or the compliance with the study.

Trial design

30 participants in 1 patient group

Experimental group
CLL/SLL patients who are slowly responding to ibrutinib are switched to orelabrutinib.
Drug: orelabrutinib

Trial contacts and locations



Central trial contact

Shenmiao Yang

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems